What it sells
Turns routine blood and cytology imaging into genomic insights for hematology labs.
Business model breakdown
Buyer: who owns the budget?
UnverifiedLab directors of hematology and cytopathology diagnostic labs.
Trigger: what makes them buy now?
Molecular testing is costly, slow and complex; fewer than half of US patients get guideline-recommended testing like NGS.
Workflow: what inputs become what output?
Integrates with the lab's imaging hardware, analyses whole-slide images of routine smears for genomic biomarkers, and triages samples before conventional NGS/molecular testing.
Economics: what it saves and how it charges
UnverifiedSoftware sold to labs that integrates with their imaging hardware to triage molecular testing; value claim is faster turnaround and less NGS cost; pricing not published.
Distribution: how it reaches customers
UnverifiedDirect sales to diagnostic laboratories (contact form).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-05-06 | — | €2.8M | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.